Premium Oteseconazole API in Pakistan: Reliable Raw Material Supply for Pharmaceutical Formulators

Product Name: Oteseconazole (Active Pharmaceutical Ingredient)

Supplier / Distributor: Morgan

Therapeutic Category: Tetrazole Antifungal / CYP51 Inhibitor

Indications: Recurrent Vulvovaginal Candidiasis (RVVC)

Compliance Notice: This technical data page is strictly for B2B pharmaceutical manufacturers, contract manufacturing organizations (CMOs), and analytical laboratories. The Oteseconazole distributed by Morgan is a highly purified Active Pharmaceutical Ingredient (API) intended exclusively for commercial formulation and laboratory R&D. It is not a finished drug product.

About Morgan: Morgan Chemicals (Pvt.) Ltd. is a pharmaceutical raw material trading and distribution company. We source APIs from DRAP-registered and internationally certified manufacturers and supply exclusively to licensed pharmaceutical companies, CMOs, and research facilities. We do not manufacture APIs or sell finished medicines.

Product Overview and Mechanism of Action

Oteseconazole is a highly targeted, orally bioavailable small-molecule Active Pharmaceutical Ingredient (API). Within the field of antimicrobial pharmacology, it represents a significant structural evolution from classic triazole and imidazole antifungals.

The defining chemical feature of Oteseconazole is its tetrazole moiety—a five-membered ring containing four nitrogen atoms and one carbon atom. This specific structure dictates its mechanism of action: the highly selective and reversible inhibition of fungal lanosterol 14α-demethylase (also known as cytochrome P450 enzyme 51, or CYP51).

Under normal physiological conditions, fungal CYP51 is essential for synthesizing ergosterol, a critical component of the fungal cell membrane. By strongly binding to the heme iron of the fungal CYP51 enzyme, Oteseconazole halts ergosterol synthesis, leading to the accumulation of toxic 14-methylated sterols. This disruption destroys the integrity and permeability of the fungal cell membrane, ultimately resulting in cell death.

Critically, the tetrazole design significantly reduces the API's affinity for human CYP450 enzymes. Unlike older azoles that frequently cause systemic liver toxicity or drug-drug interactions by inadvertently blocking human CYP pathways, Oteseconazole’s selectivity makes it a superior formulation candidate. In commercial manufacturing, it is utilized to formulate 150 mg oral solid capsules aimed specifically at combating treatment-resistant fungal strains.

Sourcing Oteseconazole in Pakistan: Morgan’s Supply Network

Commercializing modern, highly selective antifungal therapies requires a resilient and traceable raw material pipeline. Procuring advanced gynecological and antimicrobial APIs for local manufacturing often involves navigating extended lead times, stringent customs protocols, and complex regulatory compliance. Sourcing OTESECONAZOL Pakistan through Morgan’s localized distribution network mitigates these complex supply chain vulnerabilities.

Morgan sources commercial-scale and pilot-scale quantities from global manufacturing partners operating in strict adherence to ICH Q7 Good Manufacturing Practice (GMP) guidelines. Partnering with Morgan as your primary supply vendor secures several operational provisions for your manufacturing facility:

• DRAP Submission Assistance: Morgan coordinates with DRAP-registered API manufacturers to obtain and forward the necessary compliance documentation on your behalf. This includes the open part of the Drug Master File (DMF), comprehensive impurity profiles, and stability data to strictly support your Drug Regulatory Authority of Pakistan (DRAP) dossier submissions.
• Supply Chain Stability: Our localized inventory management eliminates international transit variables. Whether you require a standard clinical batch or are scaling up a high-volume OTESECONAZOLE api Pakistan procurement order, we help ensure that your commercial batch schedules and production timelines are met without costly line stoppages.
• Batch-to-Batch Uniformity: Every shipment coordinated by Morgan includes a detailed Certificate of Analysis (CoA) issued by the original manufacturer. We ensure our supplied batches maintain consistent chemical purity, controlled moisture limits, and a precise particle size distribution (PSD) for predictable behavior during compounding and capsule filling processes.

Technical Specifications for QA & R&D

The Oteseconazole API supplied by Morgan undergoes exacting analytical testing at the source to meet current international pharmacopeial standards.

• Chemical Name: (R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1-(5-(4-(2,2,2-trifluoroethoxy)phenyl)pyridin-2-yl)propan-2-ol
• CAS Number: 1340593-59-0
• Appearance: White to off-white crystalline solid powder
• Molecular Formula: C23H16F7N5O2
• Molecular Weight: 527.4 g/mol
• Assay / Purity (HPLC): ≥ 99.0%
• Solubility Profile: Insoluble in water across a pH range of 1 to 9; soluble in specific organic solvents like DMSO. Detailed solubility parameters are documented in the technical data sheet to assist analytical R&D teams with dissolution profiling.

Manufacturing and Handling Guidelines for Formulators

While Oteseconazole offers a refined safety profile regarding human CYP interactions, it is a highly potent API that carries specific embryo-fetal toxicity warnings. Facilities processing this API must enforce strict occupational exposure limits (OEL) to protect personnel on the manufacturing floor.

• Storage Conditions: Store the raw API powder in securely closed, light-resistant containers. Maintain climate-controlled conditions as specified by the batch protocol (typically controlled room temperature or refrigerated, strictly protected from excessive heat and ambient humidity) to prevent degradation.
• Occupational Safety: Personnel handling the pure API powder must follow advanced industrial containment protocols. Due to known embryo-fetal risks, processing requires maximum Personal Protective Equipment (PPE), including P3/N95 industrial respirators, double-layered chemical-resistant nitrile gloves, and full protective facility garments. Dispensing, milling, and compounding stages must be executed within dedicated negative-pressure weighing booths or closed-loop isolators to prevent inhalation of airborne particulates and facility cross-contamination.

Distributor Disclaimer: Morgan Chemicals is a pharmaceutical raw material trading and distribution company. This API is sourced from DRAP-registered, GMP-certified manufacturing partners. Morgan Chemicals does not manufacture APIs, does not hold DRAP manufacturing registration, and does not sell finished medicines. This product is supplied exclusively to licensed pharmaceutical companies, CMOs, and research facilities in Pakistan — not for individual or consumer sale.